NEW YORK (GenomeWeb News) – Quest Diagnostics this week said that it intends to sell its HemoCue point-of-care diagnostics business and will report results associated with that business, as well as the OralDNA business that it sold last month, as discontinued operations in its fourth-quarter financials. Quest said that it expects to take a charge of $89.5 million, or $.56 per share, related to the discontinued operations for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: method to detect single-nucleotide and copy-number alterations in single cells from archival tissue, and more.

China has announced new rules governing the use of stem cell treatments, Nature News reports.

Wired's Sarah Zhang expresses frustration as a microbiome study of homes uncovers expected bacteria.

A database containing genome sequences from strains of foodborne pathogens may enable regulators and companies to quickly identify outbreak sources, Reuters reports.